 |
|
|
| |
Islatravir and Ulonivirine Create a Combination With a High Barrier to Resistance In Vitro
|
| |
| |
CROI 2026
Tracy L. Diamond, Winnie Ngo, Min Xu, Silveria Rodriguez, Jay A. Grobler, Ernest Asante-Appiah
Merck & Co., Inc., Rahway, NJ, USA
• ISL+ULO combination more effectively suppressed viral breakthrough and demonstrated a higher barrier to the emergence of resistance than either compound on its own
• The compounds demonstrated complementary resistance profiles which support further clinical development of ISL/ULO as a once-weekly oral treatment for HIV-1
|
| |
|
|
|
|
|
